Incyte’s Ruxolitinib Cream demonstrates promising efficacy in TRuE-AD3 study
Incyte (Nasdaq:INCY), an esteemed biopharmaceutical giant, has unveiled compelling expanded findings from its Phase 3 TRuE-AD3 study on the ruxolitinib cream (Opzelura) for treating children ... Read More
Eli Lilly receives FDA response letter for eczema treatment lebrikizumab
Eli Lilly and Company (NYSE: LLY) has announced a recent development regarding its biologic license application (BLA) for lebrikizumab, a treatment aimed at addressing moderate-to-severe ... Read More
EMA validates LEO Pharma’s application for delgocitinib cream in chronic hand eczema
LEO Pharma A/S said that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for delgocitinib cream. Touted as a groundbreaking topical ... Read More
Arena begins ADVISE clinical trial for etrasimod in atopic dermatitis
Arena Pharmaceuticals has dosed the first subject in the phase 2 ADVISE clinical trial, which is evaluating etrasimod for the treatment of moderate-to-severe atopic dermatitis ... Read More
Galderma launches phase 3 atopic dermatitis trial for nemolizumab
Galderma, a Nestle-owned Swiss pharma company, said that it has enrolled the first patients in a phase 3 clinical study evaluating nemolizumab for the treatment ... Read More
Teva launches generic version of Elidel Cream to expand eczema treatment options
Teva Pharmaceutical Industries has unveiled its generic version of Elidel (pimecrolimus) Cream, 1%, providing a more affordable treatment option for individuals battling mild to moderate ... Read More
Skin lotion rich in good bacteria fights skin infections
Bacteria have been found to play a vital role in our immune defence, especially in treating skin infections as per a recent research published in ... Read More
Sanofi and Regeneron’s Dupixent receives FDA approval for atopic dermatitis treatment
Sanofi and Regeneron Pharmaceuticals have announced a significant advancement in dermatological care with the U.S. Food and Drug Administration (FDA) approving Dupixent (dupilumab) for the ... Read More